Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 33,200 shares, an increase of 107.5% from the February 13th total of 16,000 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average trading volume of 41,400 shares, the days-to-cover ratio is currently 0.8 days.

Evogene Trading Up 3.6 %

EVGN traded up $0.05 during trading hours on Friday, hitting $1.43. The company’s stock had a trading volume of 11,291 shares, compared to its average volume of 89,204. Evogene has a 12 month low of $1.20 and a 12 month high of $9.00. The stock has a market cap of $7.67 million, a price-to-earnings ratio of -0.32 and a beta of 1.28. The business’s 50-day moving average price is $1.53 and its 200-day moving average price is $1.98.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The business had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. During the same quarter in the previous year, the business posted ($1.30) earnings per share.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene as of its most recent SEC filing. 10.40% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Alliance Global Partners restated a “buy” rating on shares of Evogene in a research note on Friday, March 7th. StockNews.com initiated coverage on shares of Evogene in a research report on Monday, March 10th. They issued a “sell” rating on the stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.